Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Announces Quarterly Earnings Results, Misses Estimates By $0.43 EPS
Five Prime Therapeutics, Inc. (NASDAQ:FPRX) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.15) by $0.43, Briefing.com reports. Five Prime Therapeutics had a negative net margin of 250.98% and a negative return on equity of 21.81%. The company had revenue of $7.80 million for the quarter, compared to analysts’ expectations of $8.32 million. During the same quarter in the prior year, the business posted ($0.49) earnings per share. The firm’s revenue was down 16.1% compared to the same quarter last year.
Shares of Five Prime Therapeutics (NASDAQ:FPRX) traded down 2.36% during mid-day trading on Wednesday, reaching $28.51. The company’s stock had a trading volume of 308,735 shares. The company’s 50 day moving average price is $29.68 and its 200-day moving average price is $35.36. Five Prime Therapeutics has a 1-year low of $26.27 and a 1-year high of $60.98. The company’s market capitalization is $795.34 million.
COPYRIGHT VIOLATION NOTICE: “Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Announces Quarterly Earnings Results, Misses Estimates By $0.43 EPS” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/09/five-prime-therapeutics-inc-nasdaqfprx-announces-quarterly-earnings-results-misses-estimates-by-0-43-eps.html.
Several analysts have commented on FPRX shares. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a report on Friday, May 5th. Zacks Investment Research raised Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Wednesday, April 26th. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Five Prime Therapeutics currently has an average rating of “Hold” and a consensus target price of $61.40.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.